# Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

> **NCT00450983** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** muromonab-CD3
- **BIOLOGICAL:** natural killer cell therapy
- **DRUG:** fludarabine phosphate
- **DRUG:** methotrexate
- **DRUG:** thiotepa
- **GENETIC:** gene expression analysis
- **OTHER:** flow cytometry
- **OTHER:** immunologic technique
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** in vitro-treated peripheral blood stem cell transplantation
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00450983
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450983, "Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00450983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*